Sturrock N D, Lang C C, Coutie W J, Struthers A D
Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Tayside, Scotland, UK.
J Hypertens. 1995 Sep;13(9):987-91. doi: 10.1097/00004872-199509000-00008.
To investigate the role of the renin-angiotensin-aldosterone system as a homoeostatic mechanism by examining whether mild activation of the renin-angiotensin-aldosterone system could enhance cyclosporin-induced renal vasoconstriction and hypertension.
We artificially activated the renin-angiotensin-aldosterone system by two means: by pretreatment with frusemide (40 mg/day orally for 2 days) and by administering exogenous angiotensin II (1 ng/kg per min intravenously). In both cases the levels of renin-angiotensin-aldosterone system activation achieved did not by themselves alter renal blood flow, glomerular filtration rate or blood pressure. We then examined the effect of cyclosporin (10 mg/kg twice a day orally) in the presence of the activated renin-angiotensin-aldosterone system in normal humans.
Cyclosporin alone acutely altered neither glomerular filtration rate (760 versus 734ml, NS; area under the curve for placebo versus cyclosporin) nor effective renal plasma flow (4,163 versus 3,915 ml, NS; area under the curve for placebo versus cyclosporin). Co-administration of exogenous angiotensin II with cyclosporin induced a fall in effective renal plasma flow from baseline but no change in glomerular filtration rate. Frusemide pretreatment together with cyclosporin administration induced a fall in glomerular filtration rate and a fall in effective renal plasma flow. Neither exogenous angiotensin II nor frusemide pretreatment influenced the blood pressure rise induced by cyclosporin. The present findings demonstrate that renin-angiotensin-aldosterone system activation augments cyclosporin-induced renal vasoconstriction but not cyclosporin-induced systemic vasoconstriction. We suggest that the renin-angiotensin-aldosterone system suppression, which normally occurs with cyclosporin, may be a homoeostatic mechanism to help prevent cyclosporin-induced renal vasoconstriction. The renin-angiotensin-aldosterone system appears, however, to play little or no role in mediating or preventing the initial increase in blood pressure caused by cyclosporin. Furthermore, frusemide is commonly prescribed together with cyclosporin even though this combination has the potential to cause a marked increase in renal dysfunction.
通过研究肾素 - 血管紧张素 - 醛固酮系统的轻度激活是否会增强环孢素诱导的肾血管收缩和高血压,来探讨该系统作为一种稳态机制的作用。
我们通过两种方式人工激活肾素 - 血管紧张素 - 醛固酮系统:一种是用速尿预处理(每天口服40毫克,共2天),另一种是静脉注射外源性血管紧张素II(每分钟1纳克/千克)。在这两种情况下,所达到的肾素 - 血管紧张素 - 醛固酮系统激活水平本身并未改变肾血流量、肾小球滤过率或血压。然后我们在正常人体内激活的肾素 - 血管紧张素 - 醛固酮系统存在的情况下,研究环孢素(每天口服两次,每次10毫克/千克)的作用。
单独使用环孢素既未急性改变肾小球滤过率(760对734毫升,无显著性差异;安慰剂与环孢素的曲线下面积),也未改变有效肾血浆流量(4163对3915毫升,无显著性差异;安慰剂与环孢素的曲线下面积)。外源性血管紧张素II与环孢素联合使用导致有效肾血浆流量从基线下降,但肾小球滤过率无变化。速尿预处理与环孢素给药一起导致肾小球滤过率下降和有效肾血浆流量下降。外源性血管紧张素II和速尿预处理均未影响环孢素引起的血压升高。目前的研究结果表明,肾素 - 血管紧张素 - 醛固酮系统激活会增强环孢素诱导的肾血管收缩,但不会增强环孢素诱导的全身血管收缩。我们认为,环孢素通常会引起的肾素 - 血管紧张素 - 醛固酮系统抑制,可能是一种有助于预防环孢素诱导的肾血管收缩的稳态机制。然而,肾素 - 血管紧张素 - 醛固酮系统在介导或预防环孢素引起的血压初始升高方面似乎作用很小或没有作用。此外,速尿通常与环孢素一起使用,尽管这种联合使用有可能导致肾功能障碍显著增加。